| CAS | 2002-44-0 |
| Sequence | H-Pro-Leu-Gly-NH2 |
| Sequence Single | H-Pro-Leu-Gly-NH2 |
| Molecular Formula | C13H24N4O3 |
| Molecular Weight | 284.36 |
| Synonyms | MIF-I, Melanostatin, Melanotropin Release-Inhibiting Factor, MSH Release Inhibiting Factor, amide |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Di- and Tripeptides|Pituitary & Hypothalamic Hormones |
| Description | Melanocyte-Stimulating Hormone-Release Inhibiting Factor also called MIF-I, Melanostatin, Melanotropin Release-Inhibiting Factor, MSH Release Inhibiting Factor, amide, an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects of morphine and stress-induced analgesia (SIA). MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB). |
| References | 1. Identification of two related pentapeptides from the brain with potent opiate agonist activity. J.Hughes et al., Nature, 258, 577 (1975) 2. Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide. S.Chiu and R.K.Mishra, Eur. J. Pharmacol., 53, 119 (1979) 3. Prolyl-leucyl-glycinamide, cyclo(leucylglycine), and derivatives block development of physical dependence on morphine in mice. R.Walter et al., Proc. Natl. Acad. Sci. USA, 76, 518 (1979) 4. On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use. S.Björkman and H.Sievertsson, Naunyn-Schmiedeberg’s Arch. Pharmacol., 298, 79 (1977) 5. Antiopioid properties of the TYR-MIF-1 family. Bocheva A, et, al. Methods Find Exp Clin Pharmacol. 2004 Nov;26(9):673-7. 6. Melanostatin (NPY) inhibited electrical activity in frog melanotrophs through modulation of K+, Na+ and Ca2+ currents. Valentijn JA, et, al. J Physiol. 1994 Mar 1;475(2):185-95. 7. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny. Saleh MI, et, al. Peptides. 1989 Jan-Feb;10(1):35-9. |